MyoKardia Inc. (MYOK) Is Surging On Phase 2 Study Results

MyoKardia Inc. (MYOK) announced Monday morning that its Phase 2 PIONEER-HCM study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy patients met its primary endpoint.

from RTT - Hot Stocks http://ift.tt/2uzCpJO
via IFTTT